Detalhe da pesquisa
1.
Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions.
Hum Vaccin Immunother
; 15(9): 2090-2105, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30829100
2.
Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial.
Am J Trop Med Hyg
; 93(3): 454-460, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26149862
3.
A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto Rico.
Am J Trop Med Hyg
; 93(3): 441-453, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26175027
4.
A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults.
Am J Trop Med Hyg
; 88(1): 73-88, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23208878
5.
A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. military recruits.
Vaccine
; 31(28): 2963-71, 2013 Jun 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-23623865
6.
The seroprevalence and seroincidence of dengue virus infection in western Kenya.
Travel Med Infect Dis
; 9(5): 246-8, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21778117